← Who reports today · Health Care
ABT · Q2 2026
Archived report (Q2 2026). Latest deep dive →
The quarter in brief
Reported sales jumped 13% on the Exact Sciences acquisition and a comparable 4.8% organic gain, but GAAP net income fell 48% as amortization, acquisition costs, a legal reserve charge and higher interest expense swamped the top-line growth.
Net Earnings
$928M
down 47.8% y/y
Net Sales
$12,593M
up 13.0% y/y
Operating Earnings
$1,693M
down 17.5% y/y
Gross Margin
$6,610M
up 5.4% y/y
All figures in $M.
| Line item | Amount and change |
|---|---|
| Nutrition | $2,144 · −3.1% |
| Diagnostics | $3,092 · +42.3% |
| Established Pharmaceuticals | $1,499 · +8.4% |
| Medical Devices | $5,858 · +9.0% |
| Net Sales | $12,593 · +13.0% |
| Cost of Products Sold | $5,983 · +9.7% |
| Gross Margin | $6,610 · +5.4% · 52.5% margin |
| Intangible Amortization* | $658 · +56.8% |
| R&D | $892 · +22.9% |
| SG&A | $3,367 · +9.3% |
| Operating Earnings | $1,693 · −17.5% · 13.4% margin |
| Interest & Other, net | −$169 net expense |
| Earnings Before Taxes | $1,524 · −29.1% |
| Taxes on Earnings | $596 · +60.8% · 39.1% rate |
| Net Earnings | $928 · −47.8% · $0.53 diluted EPS |
Verdict: reported sales jumped 13% on the Exact Sciences acquisition and a comparable 4.8% organic gain, but GAAP net income fell 48% as amortization, acquisition costs, a legal reserve charge and higher interest expense swamped the top-line growth.
Returned $2.1B to shareholders via dividends and buybacks in Q2; 410th consecutive quarterly dividend of $0.63/share declared; FY2026 adjusted EPS guidance raised to $5.45-$5.60; comparable sales growth guidance reaffirmed at 6.5-7.5%.
Source and notation
* marks non-cash / ≈ estimated. Source: Abbott Laboratories press release / 10-Q (SEC EDGAR).
Open as an image: ABT, Q2 2026 (PNG) ↗ · for sharing and presentations · free to reuse, CC BY 4.0
Cite / embed this chart
Free to use in articles, research and social posts with credit to Who Reports Today and a link — licensed under CC BY 4.0 (terms).
Chart: “ABT Q2 2026: where the revenue went” by Who Reports Today, https://whoreportstoday.com/t/abt/q2-2026. Licensed under CC BY 4.0.
<figure> <a href="https://whoreportstoday.com/t/abt/q2-2026"><img src="https://whoreportstoday.com/t/abt/q2-2026/sankey.png" alt="ABT Q2 2026: where the revenue went" loading="lazy" style="max-width:100%;height:auto"></a> <figcaption>Source: <a href="https://whoreportstoday.com/t/abt/q2-2026">Who Reports Today</a>, licensed under <a href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</a></figcaption> </figure>
https://whoreportstoday.com/t/abt/q2-2026/sankey.png
<a href="https://whoreportstoday.com/t/abt/q2-2026">ABT Q2 2026 earnings chart (Who Reports Today)</a>
This is an archived report: the image at this link won’t change. If you change the chart (crop, translate), say so in the credit. Company logos and trademarks are not covered by the license.
- Reported sales growth of 13.0% is inflated by the March 2026 Exact Sciences acquisition (Cancer Diagnostics, +$811M) and prior-year comps; comparable sales growth was 4.8%.
- GAAP net income of $928M vs adjusted $2,290M — a $1.36B after-tax gap from intangible amortization ($658M), acquisition costs, a $385M legal reserve, and investment impairments.
- Diagnostics reported sales +42.3% almost entirely due to Exact Sciences; Rapid/Molecular Diagnostics actually declined 7.3% y/y on lower respiratory test sales.
- Nutrition sales fell 3.1% reported (-3.6% comparable) on lower volumes, though sequential sales rose $127M vs Q1 on pricing actions and new launches.
- Interest expense, net spiked to $299M from $50M y/y, reflecting acquisition-related debt; tax rate jumped to 39.1% GAAP vs 17.3% a year ago due to one-time tax position resolutions and deferred tax benefit adjustments.
- Medical Devices remained the growth engine (+9.0% reported, +8.4% comparable), led by Electrophysiology (+14.0%) and continued double-digit CGM growth in Diabetes Care.
What distorts the picture in this report and what to watch beyond the headlines.
ABT — Abbott Laboratories develops healthcare products, including medical devices, diagnostics, and nutritional formulas.
The company operates globally, with its headquarters in Abbott Park, Illinois.
Heads-up
- net income fell 48% y/y in Q2 2026
Most likely because nutrition sales fell 3.1% reported (-3.6% comparable) on lower volumes; interest expense, net spiked to $299M from $50M y/y, reflecting acquisition-related debt; costs grew faster than revenue (intangible amortization* +57% y/y, taxes on earnings +61% y/y, r&d +23% y/y). Based on the Q2 2026 report.
Company filings on SEC EDGAR ↗More reports: ALGN · Q2 2026 · AMGN · Q2 2026 · BAX · Q2 2026 · BDX · Q3 FY2026 · BIIB · Q2 2026 · BMY · Q2 2026 · BSX · Q2 2026 · CAH · Q4 FY2026 · CI · Q2 2026 · CNC · Q2 2026 · all reports